Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.
Traders rush for the exits in response to the company's fiscal-fourth-quarter earnings report and to an announced delay in two of its ongoing clinical studies.
Multiple programs are in development.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.